Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02643303
Title A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications

kidney cancer

melanoma

sarcoma

breast cancer

Advanced Solid Tumor

head and neck squamous cell carcinoma

Merkel cell carcinoma

urinary bladder cancer

primary cutaneous T-cell non-Hodgkin lymphoma

Therapies

Durvalumab + Poly ICLC

Tremelimumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Facility Atlanta Georgia 30322 United States Details
Research Facility Lebanon New Hampshire 03756 United States Details
Research Facility Buffalo New York 14263 United States Details
Research Facility New York New York 10029 United States Details
Research Facility Cleveland Ohio 44195 United States Details
Research Facility Toledo Ohio 43614 United States Details
Research Facility Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field